132 related articles for article (PubMed ID: 23137166)
21. A randomized phase IIb presurgical study of finasteride vs. low-dose flutamide vs. placebo in men with prostate cancer. Efficacy monitored by karyometry.
Montironi R; Bartels PH; DeCensi A; Puntoni M; Hurle R; Decobelli O; Carmignani G; Mazzucchelli R; Bartels HG; Alberts DS; Maffezzini M
Urol Oncol; 2013 Jul; 31(5):557-65. PubMed ID: 21783387
[TBL] [Abstract][Full Text] [Related]
22. Increased non-prostate cancer death risk in clinically diagnosed prostate cancer.
van Leeuwen PJ; Otto SJ; Kranse R; Roobol MJ; Bul M; Zhu X; de Koning H; Schröder FH
BJU Int; 2012 Jul; 110(2):188-94. PubMed ID: 22288823
[TBL] [Abstract][Full Text] [Related]
23. Finasteride Reduces Risk of Bladder Cancer in a Large Prospective Screening Study.
Morales EE; Grill S; Svatek RS; Kaushik D; Thompson IM; Ankerst DP; Liss MA
Eur Urol; 2016 Mar; 69(3):407-10. PubMed ID: 26320383
[TBL] [Abstract][Full Text] [Related]
24. Use of β-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy.
Grytli HH; Fagerland MW; Fosså SD; Taskén KA; Håheim LL
Prostate; 2013 Feb; 73(3):250-60. PubMed ID: 22821802
[TBL] [Abstract][Full Text] [Related]
25. Comparative analysis of alpha-blocker utilization in combination with 5-alpha reductase inhibitors for enlarged prostate in a managed care setting among Medicare-aged men.
Issa MM; Lin PJ; Eaddy MT; Shah MB; Davis EA
Am J Manag Care; 2008 May; 14(5 Suppl 2):S160-6. PubMed ID: 18611090
[TBL] [Abstract][Full Text] [Related]
26. Prostate cancer risk among users of finasteride and alpha-blockers - a population based case-control study.
Murtola TJ; Tammela TL; Määttänen L; Hakama M; Auvinen A
Eur J Cancer; 2007 Mar; 43(4):775-81. PubMed ID: 17251005
[TBL] [Abstract][Full Text] [Related]
27. Effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer.
Stanczyk FZ; Azen CG; Pike MC
J Steroid Biochem Mol Biol; 2013 Nov; 138():10-6. PubMed ID: 23474436
[TBL] [Abstract][Full Text] [Related]
28. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
Lepor H; Williford WO; Barry MJ; Brawer MK; Dixon CM; Gormley G; Haakenson C; Machi M; Narayan P; Padley RJ
N Engl J Med; 1996 Aug; 335(8):533-9. PubMed ID: 8684407
[TBL] [Abstract][Full Text] [Related]
29. Clinical progression, acute urinary retention, prostate-related surgeries, and costs in patients with benign prostatic hyperplasia taking early versus delayed combination 5α-reductase inhibitor therapy and α-blocker therapy: a retrospective analysis.
Morlock R; Goodwin B; Gomez Rey G; Eaddy M
Clin Ther; 2013 May; 35(5):624-33. PubMed ID: 23583026
[TBL] [Abstract][Full Text] [Related]
30. Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up.
Bañez LL; Blake GW; McLeod DG; Crawford ED; Moul JW
BJU Int; 2009 Aug; 104(3):310-4. PubMed ID: 19239458
[TBL] [Abstract][Full Text] [Related]
31. A population-based study of the risk of osteoporosis and fracture with dutasteride and finasteride.
Antoniou T; Macdonald EM; Yao Z; Gomes T; Tadrous M; Ho JM; Mamdani MM; Juurlink DN;
BMC Musculoskelet Disord; 2018 May; 19(1):160. PubMed ID: 29789004
[TBL] [Abstract][Full Text] [Related]
32. The impact of 5-alpha-reductase inhibitors on the number of prostatectomies for benign prostatic hyperplasia.
Agha AH; Roy JB; Culkin DJ; Lyon K
Adv Ther; 1995; 12(6):361-6. PubMed ID: 10163332
[TBL] [Abstract][Full Text] [Related]
33. 5α-Reductase Inhibitors and Risk of Prostate Cancer Death.
Bonde Miranda T; Garmo H; Stattin P; Robinson D
J Urol; 2020 Oct; 204(4):714-719. PubMed ID: 32243243
[TBL] [Abstract][Full Text] [Related]
34. Risk of Prostate Cancer in Men Treated With 5α-Reductase Inhibitors-A Large Population-Based Prospective Study.
Wallerstedt A; Strom P; Gronberg H; Nordstrom T; Eklund M
J Natl Cancer Inst; 2018 Nov; 110(11):1216-1221. PubMed ID: 29548030
[TBL] [Abstract][Full Text] [Related]
35. Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes.
Lotan Y; Cadeddu JA; Lee JJ; Roehrborn CG; Lippman SM
J Clin Oncol; 2005 Mar; 23(9):1911-20. PubMed ID: 15774783
[TBL] [Abstract][Full Text] [Related]
36. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
Naslund MJ; Miner M
Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
[TBL] [Abstract][Full Text] [Related]
37. Impact of 5α-reductase inhibitors on men followed by active surveillance for prostate cancer.
Finelli A; Trottier G; Lawrentschuk N; Sowerby R; Zlotta AR; Radomski L; Timilshina N; Evans A; van der Kwast TH; Toi A; Jewett MA; Trachtenberg J; Fleshner NE
Eur Urol; 2011 Apr; 59(4):509-14. PubMed ID: 21211899
[TBL] [Abstract][Full Text] [Related]
38. Regular Aspirin Use and the Risk of Lethal Prostate Cancer in the Physicians' Health Study.
Downer MK; Allard CB; Preston MA; Gaziano JM; Stampfer MJ; Mucci LA; Batista JL
Eur Urol; 2017 Nov; 72(5):821-827. PubMed ID: 28189429
[TBL] [Abstract][Full Text] [Related]
39. Population-based analysis of treatment modalities and survival for clinically localized small-cell carcinoma of the prostate.
Weiner AB; Patel SG; Richards KA; Szmulewitz RZ; Eggener SE
Prostate Cancer Prostatic Dis; 2014 Sep; 17(3):286-91. PubMed ID: 25027862
[TBL] [Abstract][Full Text] [Related]
40. Hormonal manipulation with finasteride or oral contraception does not influence incidence of renal cell carcinoma.
Kabra A; Gelfond J; Liss MA
Eur J Cancer Prev; 2018 Sep; 27(5):449-452. PubMed ID: 28338531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
